Tallac Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Tallac Therapeutics is a privately held biotechnology company headquartered in Burlingame, California, focused on cancer immunotherapy. It develops therapies that engage both innate and adaptive immune responses to tackle cancer, with a pipeline built around a platform that attaches a Toll-like receptor 9 agonist to antibodies for systemic, targeted immune activation. Several candidates based on this approach are in discovery and preclinical development, reflecting an early-stage research program. The company aims to address resistance and nonresponse to existing cancer treatments through immunotherapeutic strategies, seeking partnerships with researchers and industry players to advance its programs. A collaboration with Selexis to support its immunotherapies was announced in 2021. In May 2022, Tallac reported FDA clearance of an IND for TAC-001, its first-in-class TLR9 agonist antibody conjugate for patients with advanced solid tumors.

Get verified Tallac Therapeutics emails free

Company overview Employee directory